GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

ETON · Jun 30, 2025

Eton Pharmaceuticals, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]

Inspectable configuration

State dimensions

Filing0001437749-25-025444General Corporate

Capex intensityRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.capex_revenue_ratio

0.00% · OPTIONAL · NOT_ENOUGH_HISTORY

Operating cash generationRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

42.05% · OPTIONAL · NOT_ENOUGH_HISTORY

Revenue growthRAWCurrent state valid · history insufficient

Evidence method

Yoy · gp.fundamentals.revenue

108.60% · CORE · NOT_ENOUGH_HISTORY

Inventory pressureRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

125.69% · OPTIONAL · NOT_ENOUGH_HISTORY

Gross marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.gross_margin

63.00% · CORE · NOT_ENOUGH_HISTORY

Operating marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.operating_margin

-7.79% · CORE · NOT_ENOUGH_HISTORY

R&D intensityRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

19.61% · OPTIONAL · NOT_ENOUGH_HISTORY

SBC intensityRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

11.07% · OPTIONAL · NOT_ENOUGH_HISTORY

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History11 statesHistory building

Dec 31, 20230/8 normalizedLevel 3 Mar 31, 20240/7 normalizedLevel 3 Jun 30, 20240/7 normalizedLevel 3 Sep 30, 20240/7 normalizedLevel 3 Dec 31, 20240/9 normalizedLevel 3 Mar 31, 20250/9 normalizedLevel 3 Jun 30, 20250/8 normalizedLevel 3 Sep 30, 20250/8 normalizedLevel 3 Dec 31, 20257/9 normalizedLevel 3 Mar 31, 20267/8 normalizedLevel 3 Jun 30, 20267/8 normalizedLevel 3

Period transition

What moved in the state?

Cash Generation Increased

Previous: 12.09%
Current: 42.05%
Delta: 29.96%

Growth Decreased

Previous: 116.95%
Current: 108.60%
Delta: -8.35%

Inventory Pressure Increased

Previous: 78.82%
Current: 125.69%
Delta: 46.88%

Margin Increased

Previous: 57.06%
Current: 63.00%
Delta: 5.94%

Profitability Decreased

Previous: -2.72%
Current: -7.79%
Delta: -5.07%

R And D Intensity Increased

Previous: 6.72%
Current: 19.61%
Delta: 12.89%

Sbc Intensity Increased

Previous: 6.94%
Current: 11.07%
Delta: 4.13%

Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.

Research Graph

Related governed research

Transitioned To · ETON Fundamental State →Has State · Eton Pharmaceuticals, Inc. →Transitioned To · ETON Fundamental State →Transitioned To · ETON CASH_GENERATION_INCREASED →Transitioned To · ETON GROWTH_DECREASED →Transitioned To · ETON INVENTORY_PRESSURE_INCREASED →Transitioned To · ETON MARGIN_INCREASED →Transitioned To · ETON PROFITABILITY_DECREASED →Transitioned To · ETON R_AND_D_INTENSITY_INCREASED →Transitioned To · ETON SBC_INTENSITY_INCREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.